Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Single-center, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MDI-1228_mesylate Ophthalmic Solution by Local Instillation in Adult Healthy Volunteers

NCT05969236 is registered in ClinicalTrials.gov with Shanghai Medinno Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05969236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Single-center, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MDI-1228_mesylate Ophthalmic Solution by Local Instillation in Adult Healthy Volunteers
Lead sponsor
Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 6, 2023
Completion date
May 30, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic conjunctivitis